HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. GANX has been the topic of a number of other reports. Chardan Capital reissued a buy rating and set a […]